×
Liquidia Technologies Net Cash Flow 2018-2025 | LQDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Liquidia Technologies net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
Liquidia Technologies Net Cash Flow 2018-2025 | LQDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Liquidia Technologies net cash flow from 2018 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.5B
Amgen (AMGN)
$159.7B
Gilead Sciences (GILD)
$139.4B
Vertex Pharmaceuticals (VRTX)
$121.3B
Bristol Myers Squibb (BMY)
$96.3B
GSK (GSK)
$78.4B
CSL (CSLLY)
$77.4B
Regeneron Pharmaceuticals (REGN)
$61.6B
Alnylam Pharmaceuticals (ALNY)
$41.2B
Argenex SE (ARGX)
$34.4B
BioNTech SE (BNTX)
$26.7B
Royalty Pharma (RPRX)
$20.4B
Biogen (BIIB)
$19.5B
Insmed (INSM)
$19.3B
Illumina (ILMN)
$15.6B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.8B
Incyte (INCY)
$13.5B
Moderna (MRNA)
$12.7B
Exelixis (EXEL)
$12.4B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.4B
Bio-Techne Corp (TECH)
$8.2B
Roivant Sciences (ROIV)
$7.9B
Regencell Bioscience Holdings (RGC)
$7.3B